ICREC Research Program, Health Science Research Institute Germans Trias i Pujol (IGTP), Can Ruti Campus, Badalona, Spain; CIBERCV, Instituto de Salud Carlos III, Madrid, Spain.
ICREC Research Program, Health Science Research Institute Germans Trias i Pujol (IGTP), Can Ruti Campus, Badalona, Spain; CIBERCV, Instituto de Salud Carlos III, Madrid, Spain; REMAR-IVECAT Group, Health Science Research Institute Germans Trias i Pujol (IGTP), Can Ruti Campus, Badalona, Spain; Department of Cell Biology, Physiology and Immunology, Universitat Autònoma de Barcelona, Bellaterra, Spain.
Biomed Pharmacother. 2022 Mar;147:112683. doi: 10.1016/j.biopha.2022.112683. Epub 2022 Feb 7.
Compelling evidence supports the therapeutic benefit of extracellular vesicles (EVs). EVs are nanostructures with a lipid bilayer membrane that are secreted by multiple cells, including mesenchymal stromal cells (MSCs), as means of cellular communication. MSC-EVs, resembling their MSC origin, carry protected immunomodulatory and pro-regenerative cargoes to targeted neighboring or distant cells and tissues. Though treatments focused on MSC-EVs have emerged as greatly versatile approaches to modulate multiple inflammatory-related conditions, crucial concerns, including the possibility of increasing therapeutic outcomes by pre-conditioning parental MSCs or engineering derived EVs and clarification of the most relevant mechanisms of action, remain. Here, we summarize the large amount of preclinical research surrounding the modulation of beneficial effects by MSC-EVs.
大量证据支持细胞外囊泡 (EVs) 的治疗益处。EVs 是一种具有脂质双层膜的纳米结构，由包括间充质基质细胞 (MSCs) 在内的多种细胞分泌，作为细胞通讯的一种方式。MSC-EVs 与其 MSC 来源相似，携带受保护的免疫调节和促再生货物，靶向邻近或远处的细胞和组织。虽然专注于 MSC-EVs 的治疗方法已成为调节多种炎症相关疾病的多功能方法，但仍存在一些关键问题，包括通过预处理亲代 MSCs 或工程衍生 EVs 来增加治疗效果的可能性，以及阐明最相关的作用机制。在这里，我们总结了大量围绕 MSC-EVs 调节有益作用的临床前研究。
